Updated On: 01 May, 2024 10:19 AM IST | New Delhi | IANS
In India, almost 90 per cent of people who received Covid-19 vaccine, received the AstraZeneca vaccine which in India is called Covishield

Image for representational purposes only. Photo Courtesy: iStock
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca’s Covid vaccine, and the benefits far outweigh the risks of the jab, said doctors here on Tuesday.
This comes after reports said that AstraZeneca has for the first time accepted in court documents that its vaccine, developed in partnership with Oxford University, can raise the risk of a rare and serious blood clot.